Literature DB >> 19733595

Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?

Joel N Blankson1.   

Abstract

Elite controllers (EC) are HIV-1 infected patients control viral replication to a level of <50 copies/ml without antiretroviral therapy. These patients are also known as elite suppressors, or HIV controllers, and they differ from traditional long-term non-progressors (LTNPs) who maintain stable CD4 counts and are asymptomatic without antiretroviral therapy. Recent studies suggest that many EC are infected with replication-competent virus. Thus it appears that host factors such as innate immunity, the humoral immune response, and the cellular immune response are involved in the suppression of viral replication in EC. This article will review the effector mechanisms that are thought to play a role in the remarkable control of viral replication seen in these patients. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19733595      PMCID: PMC2814919          DOI: 10.1016/j.antiviral.2009.08.007

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  115 in total

1.  Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors.

Authors:  Mathias Lichterfeld; Danlei Mou; Thai Duong Hong Cung; Katie L Williams; Michael T Waring; Jinghe Huang; Florencia Pereyra; Alicja Trocha; Gordon J Freeman; Eric S Rosenberg; Bruce D Walker; Xu G Yu
Journal:  Blood       Date:  2008-08-26       Impact factor: 22.113

2.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

3.  HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Authors:  Brinda Emu; Elizabeth Sinclair; Hiroyu Hatano; April Ferre; Barbara Shacklett; Jeffrey N Martin; J M McCune; Steven G Deeks
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

4.  Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation.

Authors:  Amanda J Chase; Hung-Chih Yang; Hao Zhang; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

5.  CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load.

Authors:  Adriana Andrade; Justin R Bailey; Jie Xu; Frances H Philp; Thomas C Quinn; Thomas M Williams; Stuart C Ray; David L Thomas; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

6.  The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department.

Authors:  Oliver Laeyendecker; Richard E Rothman; Charlamaine Henson; Bobbi Jo Horne; Kerunne S Ketlogetswe; Chadd K Kraus; Judy Shahan; Gabor D Kelen; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

7.  Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor.

Authors:  Justin R Bailey; Karen O'Connell; Hung-Chih Yang; Yefei Han; Jie Xu; Benjamin Jilek; Thomas M Williams; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

8.  A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.

Authors:  Jason B Dinoso; Scott Y Kim; Robert F Siliciano; Joel N Blankson
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

Review 9.  HIV-1 Vif, APOBEC, and intrinsic immunity.

Authors:  Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2008-06-24       Impact factor: 4.602

10.  HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles.

Authors:  Gabriel Catano; Hemant Kulkarni; Weijing He; Vincent C Marconi; Brian K Agan; Michael Landrum; Stephanie Anderson; Judith Delmar; Vanessa Telles; Li Song; John Castiblanco; Robert A Clark; Matthew J Dolan; Sunil K Ahuja
Journal:  PLoS One       Date:  2008-11-04       Impact factor: 3.240

View more
  42 in total

1.  CD4 T-cell regeneration in HIV-1 elite controllers.

Authors:  Yue Yang; Maha Al-Mozaini; Maria J Buzon; Jill Beamon; Sara Ferrando-Martinez; Ezequiel Ruiz-Mateos; Eric S Rosenberg; Florencia Pereyra; Xu G Yu; Mathias Lichterfeld
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

2.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage.

Authors:  Kevin O Saunders; Cavin Ward-Caviness; Robert J Schutte; Stephanie A Freel; R Glenn Overman; Nathan M Thielman; Coleen K Cunningham; Thomas B Kepler; Georgia D Tomaras
Journal:  Cell Immunol       Date:  2010-10-27       Impact factor: 4.868

4.  Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors.

Authors:  Maria Salgado; Gregory D Kirk; Andrea Cox; Alleluiah Rutebemberwa; Yvonne Higgins; Jacquie Astemborski; David L Thomas; Chloe L Thio; Mark S Sulkowski; Joel N Blankson
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

5.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

Review 6.  Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?

Authors:  Daniel C Rogan; Mark Connors
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-11       Impact factor: 5.071

7.  HIV type 1-mediated downregulation of HLA-B*57/B*5801 proteins on elite suppressor CD4+ T cells.

Authors:  Maame Efua S Sampah; Christina M Ceccato; Joel N Blankson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-04       Impact factor: 2.205

8.  Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.

Authors:  Wendy E Walker; Sebastian Kurscheid; Samit Joshi; Charlie A Lopez; Gerald Goh; Murim Choi; Lydia Barakat; John Francis; Ann Fisher; Michael Kozal; Heidi Zapata; Albert Shaw; Richard Lifton; Richard E Sutton; Erol Fikrig
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

9.  T cell receptors for the HIV KK10 epitope from patients with differential immunologic control are functionally indistinguishable.

Authors:  Alok V Joglekar; Zhe Liu; Jeffrey K Weber; Yong Ouyang; John D Jeppson; Won Jun Noh; Pedro A Lamothe-Molina; Huabiao Chen; Seung-Gu Kang; Michael T Bethune; Ruhong Zhou; Bruce D Walker; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-07       Impact factor: 11.205

10.  Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

Authors:  Rikke Olesen; Selena Vigano; Thomas A Rasmussen; Ole S Søgaard; Zhengyu Ouyang; Maria Buzon; Arman Bashirova; Mary Carrington; Sarah Palmer; Christel R Brinkmann; Xu G Yu; Lars Østergaard; Martin Tolstrup; Mathias Lichterfeld
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.